Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?

Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.